Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2010

Open Access 01-12-2010 | Case report

Necrotising fasciitis of the shoulder in association with rheumatoid arthritis treated with etanercept: a case report

Authors: Andrew Smyth, Diarmaid D Houlihan, Helen Tuite, Catherine Fleming, Thomas A O'Gorman

Published in: Journal of Medical Case Reports | Issue 1/2010

Login to get access

Abstract

Introduction

Necrotising fasciitis is a severe infection characterised by the fulminant destruction of tissue with associated systemic signs of sepsis and toxicity. Etanercept is a fully human fusion protein that inhibits tumor necrosis factor and the inflammatory cascade. It is effective in the treatment of many disorders but concerns regarding severe life threatening infections have been raised in multiple reports.

Case presentation

We present the case of a 39-year-old Caucasian man, who presented with sudden onset of severe and progressive neck and left shoulder pain, with a two-year history of seronegative rheumatoid arthritis treated with azathoprine and etanercept. On examination the left side of his neck and his left shoulder were oedematous, tender with an erythematous rash and his active range of movement was limited. Magnetic resonance imaging of his shoulder showed extensive oedema of the subcutaneous and intramuscular fat of the left lower neck consistent with fasciitis. He was treated medically and made a good recovery.

Conclusion

Our patient, while having a pre-existing increased mortality risk, had a serious infection which responded well to optimum medical treatment without the need for surgery. As anti tumor necrosis factor agents are frequently associated with infection, including tuberculous infection, this case highlights the need for a high index of suspicion for other severe bacterial infections in patients on immunosuppressants.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343: 1586-1593. 10.1056/NEJM200011303432201.CrossRefPubMed Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343: 1586-1593. 10.1056/NEJM200011303432201.CrossRefPubMed
2.
go back to reference Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Bengamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996, 334: 1697-1702. 10.1056/NEJM199606273342603.CrossRefPubMed Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Bengamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996, 334: 1697-1702. 10.1056/NEJM199606273342603.CrossRefPubMed
3.
go back to reference O'Dell JR: Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?. N Engl J Med. 1999, 340: 310-312. 10.1056/NEJM199901283400411.CrossRefPubMed O'Dell JR: Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?. N Engl J Med. 1999, 340: 310-312. 10.1056/NEJM199901283400411.CrossRefPubMed
4.
go back to reference Reddy JG, Loftus EV: Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006, 35: 837-855. 10.1016/j.gtc.2006.09.008.CrossRefPubMed Reddy JG, Loftus EV: Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006, 35: 837-855. 10.1016/j.gtc.2006.09.008.CrossRefPubMed
5.
go back to reference Kavanagh PM, Gilmartin JJ, O'Donnell J, O'Flanagan D: Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir Med J. 2008, 101: 6-7.PubMed Kavanagh PM, Gilmartin JJ, O'Donnell J, O'Flanagan D: Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir Med J. 2008, 101: 6-7.PubMed
6.
go back to reference Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Sazne T, Romanus V, Klareskog L, Feltelius N: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005, 52: 1986-1992. 10.1002/art.21137.CrossRefPubMed Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Sazne T, Romanus V, Klareskog L, Feltelius N: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005, 52: 1986-1992. 10.1002/art.21137.CrossRefPubMed
7.
go back to reference Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007, 56: 1754-1764. 10.1002/art.22600.CrossRefPubMed Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007, 56: 1754-1764. 10.1002/art.22600.CrossRefPubMed
8.
go back to reference Kroesen S, Widmer AF, Tyndall A, Hasler P: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003, 42: 617-621. 10.1093/rheumatology/keg263.CrossRef Kroesen S, Widmer AF, Tyndall A, Hasler P: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003, 42: 617-621. 10.1093/rheumatology/keg263.CrossRef
9.
go back to reference Childers BJ, Potyondy LD, Nachreiner R, Rogers FR, Childers ER, Oberg KC, Hendricks DL, Hardesty RA: Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg. 2002, 68: 109-116.PubMed Childers BJ, Potyondy LD, Nachreiner R, Rogers FR, Childers ER, Oberg KC, Hendricks DL, Hardesty RA: Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg. 2002, 68: 109-116.PubMed
10.
go back to reference Praba-Egge AD, Lanning D, Broderick TJ, Yelon JA: Necrotizing fasciitis of the chest and abdominal wall arising from an empyema. J Trauma. 2004, 56: 1356-1361. 10.1097/01.TA.0000042157.00868.2E.CrossRefPubMed Praba-Egge AD, Lanning D, Broderick TJ, Yelon JA: Necrotizing fasciitis of the chest and abdominal wall arising from an empyema. J Trauma. 2004, 56: 1356-1361. 10.1097/01.TA.0000042157.00868.2E.CrossRefPubMed
Metadata
Title
Necrotising fasciitis of the shoulder in association with rheumatoid arthritis treated with etanercept: a case report
Authors
Andrew Smyth
Diarmaid D Houlihan
Helen Tuite
Catherine Fleming
Thomas A O'Gorman
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2010
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-4-367

Other articles of this Issue 1/2010

Journal of Medical Case Reports 1/2010 Go to the issue